Phenobarbital tablets

Quick links to important sections

Phenobarbital tablets

Selected form

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Phenobarbital tablets

Property Description
Active ingredient Phenobarbital (phenobarbitone)
Form Oral tablet (Solid dosage form)
Pharmacological class Barbiturate, Anticonvulsant (AED)
General purpose Prevention of neuronal hyperexcitability
Origin Synthetic compound (Barbituric acid derivative)

What Type of Medicine is Phenobarbital? (Definition, Form, and Origin)

Phenobarbital tablets are a single-ingredient pharmaceutical preparation intended for the oral route of administration, known as a solid dosage form. The sole active ingredient is phenobarbital, a compound also designated as phenobarbitone. This medicine is classified as a synthetic compound, manufactured as a chemical derivative of barbituric acid. As a long-acting agent, this specific formulation is often used in chronic neurological management to provide sustained stability.

The status of phenobarbital as a fundamental therapeutic agent reflects its global recognition and critical role in therapy. This standing is based on its established use and general acceptance in the management of specific neurological conditions worldwide.


Pharmacological Classification and Composition (Class and Chemistry)

Phenobarbital belongs to the historical barbiturate class of drugs, which function as non-selective Central Nervous System (CNS) depressants, and is therapeutically categorized as an Anticonvulsant or Antiepileptic Drug (AED). The core composition of the tablet contains only the Phenobarbital active substance combined with the necessary solid excipients required for form and stability.

The drug is characterized by potent GABAergic activity. This mechanism is noted for its unique profile among AEDs, primarily acting by magnifying inhibitory signals within the brain, thereby controlling neuronal activity.


What is the General Purpose of Phenobarbital's Action? (High-Level Mechanism and Benefit)

The general purpose of administering Phenobarbital tablets is to achieve neuronal stabilization to prevent the occurrence of uncontrolled electrical disturbances in the brain. The medicine exerts a widespread calming influence by enhancing the action of the inhibitory neurotransmitter, GABA (gamma-aminobutyric acid), essentially augmenting the brain’s natural mechanism for reducing nerve cell firing.

This mechanism results in the elevation of the seizure threshold, which reduces the likelihood of the sudden, abnormal nerve cell discharges that characterize epileptic events. The primary benefit of this action is providing the patient with long-term management and sustained control over neurological hyperexcitability, such as in the maintenance treatment for certain seizure types.

Regulatory References

  1. WHO Essential Medicines List for Phenobarbital

What side effects are possible with Phenobarbital tablets?

Possible side effects and safety information

The safety profile for phenobarbital tablets is organized according to regulatory classifications that define the types and frequencies of adverse reactions documented in clinical use. These documented reactions primarily affect the Central Nervous System (CNS), Psychiatric system, Skin, and Hepatobiliary system.

Adverse Reactions by Classification

Classification Tier Documented Reactions and Systems
Very Common / Common Drowsiness (somnolence), sedation, dizziness, ataxia, and generalized skin rash are commonly reported, often diminishing after treatment initiation. (Nervous System, Skin)
Serious Adverse Reactions Officially documented serious risks include Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), severe hepatic injury, and an increased risk of suicidal ideation and behavior. (Skin, Hepatobiliary, Psychiatric)

Population-Specific and Duration-Related Safety Notes

The official labeling includes specific safety considerations for certain patient groups and durations of exposure. Pediatric patients and older adults have a documented risk of experiencing paradoxical reactions, such as excitement or hyperactivity, rather than the expected sedation. The medicine is contraindicated in individuals with severe hepatic impairment, as defined by regulatory documents.

Furthermore, official safety information states that long-term use is associated with the risk of physical and psychological dependence and potential changes in bone mineral density. Abrupt discontinuation of treatment is explicitly documented to precipitate a severe, potentially life-threatening withdrawal syndrome, including status epilepticus.

Overdose and Emergency Response

Phenobarbital overdose primarily involves the deep depression of the Central Nervous System (CNS), which can lead to a range of manifestations from confusion, stupor, and ataxia (a sign particularly noted in children) to a profound comatose state. Official regulatory documents specify clinical signs such as depressed reflex activity, hyporeflexia, and specific pupil changes. Hypothermia is also documented as a physiological finding. Severe overdose rapidly progresses to life-threatening cardiorespiratory compromise.

The most serious outcomes documented include respiratory depression, hypoxia, and profound hypotension, potentially leading to cardiac arrest and shock syndrome. Complications such as pulmonary edema and acute renal failure are also officially noted.

Because of the inherent systemic risks, regulatory bodies mandate that immediate medical attention must be sought for any suspected overdose. Emergency services and the Poison Control Center must be contacted immediately. The required management is strictly symptomatic and supportive therapy, focusing on maintaining vital functions, such as blood pressure and adequate respiratory exchange. Procedures such as activated charcoal administration and gastric lavage are described management measures. No specific antidote is known. Monitoring requirements include the continuous observation of vital signs and potentially serial drug concentration monitoring during hospitalization.

Therapeutic Uses of Phenobarbital tablets

Phenobarbital tablets are generally used to provide support for the long-term management of neurological symptoms and symptomatic relief across specific symptomatic domains. Therapeutically, this medication is categorized across two primary areas: anticonvulsant and sedative.

Therapeutic Focus and Conditions

Phenobarbital is commonly used in the long-term management of epilepsy, applied in conditions characterized by recurrent and severe convulsions, such as generalized tonic-clonic seizures and specific forms of focal seizures. The medication is also relevant for managing acute clinical scenarios involving continuous convulsive activity. Additionally, it is relevant for its sedative properties to manage pronounced symptoms of generalized nervousness, tension, and severe difficulty sleeping (insomnia).

The key therapeutic benefit is supporting symptom control that may assist with managing the frequency and intensity of these episodes, which generally helps maintain a sense of stability for the patient.

“Supporting symptom control in chronic conditions may contribute to improved day-to-day comfort during periods of heightened symptoms.”


Quick Fact: Relief for Convulsions and Tension

Feature Description
Primary Indication Supportive management of specific recurrent seizure disorders
Symptom Relief Helps manage episodes of severe convulsions, spasms, tension, and insomnia
Key Benefit Provides support that eases the overall symptom burden and assists with maintaining stability when symptoms interfere with routine activities
Relevant Context Long-term therapeutic contexts or situations requiring temporary symptomatic assistance

Regulatory References

  1. NIH DailyMed overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Phenobarbital Tablets?

The population eligibility for Phenobarbital is strictly defined by regulatory authorities and centers on absolute non-eligibility (contraindications) and conditional use.


Absolute Non-Eligibility (Contraindications)

Phenobarbital is contraindicated for use in individuals who have a known hypersensitivity to barbiturates or a history of manifest or latent porphyria. The medicine must also not be administered to patients with marked impairment of liver function or those with severe respiratory disease where obstruction or dyspnea is evident. Use is also restricted for persons with a known previous addiction to the sedative/hypnotic group.


Conditional Use and Restrictions

Population Group Regulatory Status
Pregnancy Restricted use (Category D). Used only if clearly needed due to risk of fetal damage and neonatal withdrawal symptoms.
Lactation (Breastfeeding) Use with caution (drug present in breast milk); neonatal adverse effects reported.
Older Adults (Geriatric) Requires lower doses and careful assessment to preclude oversedation.
Renal/Hepatic Impairment Requires great caution and use of reduced dosage in marked renal or existing liver dysfunction.
Children Reports of cognitive deficits in some children; use requires great caution in infants.

Eligibility is also restricted for patients with a history of drug dependence or those presenting with acute pain, due to the risk of paradoxical excitement or symptom masking.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Phenobarbital tablets have a significant potential for drug-drug interactions, primarily due to their ability to act as a potent inducer of liver enzymes (specifically the cytochrome P450 system). This can lead to increased metabolism and decreased effectiveness of many co-administered medicines.

Clinically Significant Interactions

  • Hormonal Contraceptives: Phenobarbital can accelerate the breakdown of estrogen and/or progestin hormones, reducing the effectiveness of oral contraceptives. Patients should discuss using a backup or alternative barrier method of contraception.
  • Oral Anticoagulants: The metabolism of drugs like dicumarol is increased, which can lower their blood levels and decrease their anticoagulant effect. Dosage adjustments and frequent monitoring of blood clotting time may be necessary.
  • Central Nervous System (CNS) Depressants: Co-administration with alcohol, opioids, antihistamines, tranquilizers, and other CNS depressants can lead to additive depressant effects, causing profound sedation, respiratory depression, coma, or death. This combination should be reserved for cases where alternative options are inadequate.
  • Contraindicated Medications: Phenobarbital should not be taken with certain medications, including specific anti-HIV drugs (e.g., those combined with cobicistat), voriconazole, primidone, or other barbiturates, due to the risk of loss of therapeutic effect or increased toxicity. Strong enzyme inducers can render essential anti-HIV or antifungal medications ineffective.
  • Valproic Acid and Sodium Valproate: These medications can inhibit the breakdown of phenobarbital, potentially leading to increased phenobarbital blood levels and toxicity, requiring close monitoring and possible dose reduction.

Mechanism of Action

Phenobarbital functions primarily as a positive allosteric modulator on the gamma-aminobutyric acid type A ( GABA A) receptor complex, a ligand-gated chloride ion channel situated on the post-synaptic membranes of central nervous system neurons. The drug binds to a distinct site on the receptor, separate from the GABA neurotransmitter binding site, enhancing the inhibitory effect of endogenous GABA.

This allosteric interaction increases the duration for which the GABA A receptor's integral chloride ion channel remains open. The sustained influx of negatively charged chloride ions ( Cl^-) leads to hyperpolarization of the neuronal membrane. This increase in the transmembrane potential stabilizes the neuron, resulting in an elevated action potential threshold. Consequently, the cell becomes less excitable, reducing the probability of neurotransmission.

At sufficiently high concentrations, phenobarbital can act as a direct agonist on the GABA A receptor complex, opening the chloride channel independent of GABA binding. Additional molecular actions include inhibition of glutamate-mediated excitatory signaling, specifically by blocking AMPA/kainate receptors and modulating voltage-dependent calcium channels, further contributing to a generalized reduction in neuronal excitability. The system-level consequence is a state of central nervous system depression.

Dosage and Administration Information

Instruction Map: How to use Phenobarbital tablets — Administration Guidelines

This map summarizes the administration guidelines for Phenobarbital.

Feature Guideline
Route of Administration The tablet form is administered via the oral route. The injectable sodium salt is approved for intravenous (IV) and intramuscular (IM) routes for acute clinical use.
Dosing Schedule Adult Anticonvulsant (Maintenance): 60 mg to 200 mg per day. Pediatric Anticonvulsant: 3 mg/kg to 8 mg/kg bodyweight daily. Adult Hypnotic: 100 mg to 200 mg once daily.
Timing in Relation to Meals May be taken with or without food. Taking the medicine at bedtime is common for maintenance to manage frequency.
Preparation Requirements Tablets should be swallowed whole with water. No specific preparation or dilution is required for the solid oral form.
Age-Group Administration Rules A reduced initial dose is recommended for older adults. Dosing for patients with impaired renal or hepatic function also requires reduction.
Missed-Dose Rules If a dose is missed, it should be taken as soon as possible, unless it is nearly time for the next dose, in which case the missed dose is skipped. The dose should not be doubled.
Special Procedural Conditions Dosing requires gradual titration and monitoring of serum concentrations. Treatment must be withdrawn slowly and gradually (tapered) to avoid clinical instability.

Instruction Classifications (High-Level)

Classification Detail
Administration Method Type Oral (Primary); Intravenous/Intramuscular (Acute/Secondary).
Frequency Pattern Once daily (OD) or divided dosing (BID/TID).
Use-Context Constraints Long-term maintenance for anticonvulsant use; short-term (typically le 2 weeks) for hypnotic use.

Resulting Procedural Structure

Step sequence:

  • The medicine is taken orally at the defined mg dosage and frequency.
  • The dosage is gradually adjusted based on patient status and laboratory monitoring of drug levels.
  • For long-term use, adherence to the schedule is necessary; for short-term use, duration should not exceed the specified maximum.
  • Therapy cessation requires slow, gradual tapering of the dose over time.

Connection to the overall use protocol: The administration guidelines structure the medicine's use by establishing the oral route for routine use, setting precise dose ranges for daily intake, and dictating the frequency pattern (once daily or divided). These guidelines further emphasize the crucial procedural steps of gradual dose adjustment and tapering to ensure procedural correctness throughout the entire course of therapy.

Recent Clinical Evidence

Phenobarbital tablets: Recent Clinical Evidence

Research Evidence for Seizure Patterns

Research exploring phenobarbital's role has included Randomized Controlled Trials (RCTs) and long-term observational studies in adults and children. These studies monitored seizure frequency and the proportion of people achieving a seizure-free state. Findings describe patterns observed over many years. However, comparative evidence is lacking from recent, blinded RCTs against newer anti-seizure medications. Evidence quality for older trials is associated with limitations cited in systematic reviews.


Evidence for Acute Use

Phenobarbital was examined in time-critical situations, such as Convulsive Status Epilepticus, as a second or third-line intervention. Researchers monitored seizure cessation and neurological status at hospital discharge. This research also explored its use in Severe Alcohol Withdrawal Syndrome (AWS), where studies tracked changes in symptom severity and resource utilization. The evidence base for acute use includes older non-blinded trials, and certainty remains low regarding definitive comparisons across all available treatments.


Pediatric Evidence and Research Gaps

Research examined phenobarbital use in neonates with seizures and young children in studies exploring the recurrence of febrile convulsions. Historical long-term studies associated with the latter raised concerns regarding potential cognitive effects, leading to a shift away from its prolonged use for this purpose. Overall, evidence for long-term cognitive outcomes is not fully established. A major research gap is the lack of recent, large-scale RCTs to directly compare the medication against newer alternatives across its studied indications. Furthermore, research for historical oral sedative uses outside of acute withdrawal settings remains insufficient.

Frequently Asked Questions (FAQ)

Common questions about Phenobarbital tablets (FAQ)

Q: How quickly does Phenobarbital start working to control seizures?

According to official product information, Phenobarbital begins to work when taken by mouth (orally) within approximately 30 minutes. However, the time it takes for the drug to reach its peak level in the bloodstream, which is known as peak plasma concentration, can take several hours.

Q: Is it normal to feel extra drowsy or 'foggy' when taking Phenobarbital?

Official adverse reaction reports frequently list drowsiness (somnolence), lethargy, and a feeling of residual sedation or 'hangover' as common experiences. These effects, which users often describe as 'foggy,' may be most noticeable when treatment is initiated.

Q: Can Phenobarbital affect my mood or cause depression?

Yes, official safety information indicates that Phenobarbital has been associated with psychiatric adverse reactions. Documented effects include depression, a confusional state, and an increased risk of suicidal ideation and behavior.

Q: What kind of stomach issues or nausea are associated with Phenobarbital?

Adverse reaction data indicates that side effects related to the digestive system have been reported with Phenobarbital. These include nausea, vomiting, and constipation.

Q: Can children or infants be prescribed Phenobarbital?

Yes, Phenobarbital is officially indicated as a sedative and anticonvulsant medication for pediatric patients. However, its use in children has been linked to reports of cognitive (learning) deficits and hyperactivity.

Q: What over-the-counter pain relievers or cold medicines should be avoided with Phenobarbital?

Official warnings mention that co-administration with other Central Nervous System (CNS) depressants, such as certain sedative ingredients found in cold and allergy medicines, may produce an amplified depressant effect. Some regulatory warnings also advise caution with common pain relievers like acetaminophen (paracetamol) due to potential interactions affecting the liver.

Q: How long does Phenobarbital stay in your system after the last dose?

Phenobarbital has a very long half-life, which is the time it takes for half of the drug to be eliminated from the body. This long half-life indicates that the substance may take several days to be fully eliminated from the system.

Q: What should I know about driving or operating machinery while on Phenobarbital?

Official labeling states that the medication may impair the mental and/or physical abilities required for the performance of potentially hazardous tasks, such as driving a vehicle or operating machinery.

Q: Is there a risk of developing dependence or addiction to Phenobarbital?

Yes, regulatory documents classify Phenobarbital as 'habit-forming' and subject to control under the Federal Controlled Substances Act (Schedule IV in the US). Tolerance, physical dependence, and psychological dependence can occur, particularly with prolonged use.

Q: Can Phenobarbital interact with herbal supplements like St. John's Wort?

Phenobarbital and St. John's Wort are both known to affect liver enzymes that break down medications. Due to this mechanism, co-administration may lead to reduced Phenobarbital effectiveness and increase the chance of side effects like drowsiness and dizziness.

Q: What foods or supplements are known to interact with Phenobarbital tablets?

Long-term use of Phenobarbital is officially associated with changes in the metabolism of certain vitamins, including Vitamin D and Folic Acid. This can lead to decreased levels of these essential nutrients. Information regarding supplementation is generally provided by a healthcare provider.

Q: Can Phenobarbital interact with antibiotics?

Official drug interaction data indicates that Phenobarbital can speed up the body's breakdown of certain antibiotics, such as doxycycline and griseofulvin. This can result in a decreased therapeutic effect of the antibiotic, and clinical monitoring may be used by healthcare providers.

Q: Is it safe to take multivitamins while on Phenobarbital?

Because Phenobarbital can increase the rate at which your body breaks down certain vitamins, such as Vitamin D and folic acid, taking multivitamins may be discussed with a healthcare provider to prevent deficiencies. Information on taking over-the-counter supplements is best sourced from a healthcare provider.

Q: What is the typical timeframe for a doctor to adjust the Phenobarbital dosage?

Dose adjustment is based on a patient’s clinical response and monitoring of the drug’s level in the blood. Because Phenobarbital has a very long half-life, it may take 1 to 3 weeks to achieve stable blood levels, which influences the clinical assessment for dosage adjustments.

Q: Does Phenobarbital affect athletic performance or energy levels?

The official side effect profile lists common adverse reactions such as generalized sedation, drowsiness, and lethargy. These effects, which are related to the central nervous system, could indirectly affect an individual’s energy levels and physical performance.

Q: Is Phenobarbital the same as generic 'luminal'?

'Luminal' is a well-known historical brand name that contains the active ingredient phenobarbital. The medicine is now commonly referred to and available by its generic name, Phenobarbital.

Q: Are there any long-term side effects of taking Phenobarbital for years?

Official safety information documents several risks associated with prolonged use. These include the risk of physical/psychological dependence and a documented risk of decreased bone mineral density, which can potentially lead to weakened or brittle bones.

Q: What happens if I forget to take my Phenobarbital dose?

Regulatory warnings state that the abrupt cessation or interruption of therapy, such as missing a dose, can precipitate withdrawal symptoms. These symptoms may include delirium and convulsions, which can be severe or even life-threatening.

Q: Is Phenobarbital considered a controlled substance, and what does that mean?

Yes, Phenobarbital is subject to control under the Federal Controlled Substances Act (Schedule IV in the US). This classification indicates that the drug has an accepted medical use but also carries a potential for abuse and dependence.

Q: Can Phenobarbital cause skin rashes or sensitivity to the sun?

Official adverse reaction data lists a generalized skin rash as a commonly reported effect. More seriously, photosensitivity, which is an increased sensitivity to the sun, has also been documented, alongside rare severe skin reactions.

Q: What resources are available for people taking Phenobarbital to manage their condition?

For individuals who become pregnant while on this medication, the official product labeling points to the existence of a Pregnancy Registry, such as the North American Antiepileptic Drug Pregnancy Registry, to gather safety information.

How should Phenobarbital tablets be stored and disposed of?

Storage Requirements

Phenobarbital tablets must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C (86 F). The container must be kept tightly closed and protected from moisture. To prevent accidental ingestion, the medication must be stored in a child-resistant container and kept out of the reach of children.

Official Disposal Rules

Unused or expired phenobarbital should be disposed of by utilizing a drug take-back program if one is available. If a take-back program is not accessible, the medication may be mixed with an undesirable substance (such as dirt or coffee grounds), sealed in a container or plastic bag, and discarded in the household trash. Do not flush the tablets down the toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Phenobarbital tablets found in:

A-Z Index: